This study was undertaken to report the efficacy and safety of dexamethasone combined with rituximab, cyclosporin and intravenous immunoglobulin in the management of newly diagnosed ITP patients. dexamethasone is an agonist of the glucocorticoid receptor the results in the reduction of immune response.
https://clinicaltrials.gov/ct2/show/NCT02834468?recrs=a&cond=ITP&draw=1&rank=9
UNKNOWN RECRUITING STATUS
